Histamine-2 receptor antagonists and gastric cancer

被引：15

作者：

Johnson, AG ^{[1
]}

Jick, SS ^{[1
]}

Perera, DR ^{[1
]}

Jick, H ^{[1
]}

机构：

[1] BOSTON UNIV,MED CTR,BOSTON COLLABORAT DRUG SURVEILLANCE PROGRAM,LEXINGTON,MA 02173

来源：

EPIDEMIOLOGY | 1996年 / 7卷 / 04期

关键词：

gastric cancer; gastroesophageal cancer; case-control study; cimetidine; ranitidine; chronic use;

D O I：

10.1097/00001648-199607000-00016

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

We conducted a case-control study at Group Health Cooperative of Puget Sound to evaluate the relation between long-term histamine-2 (H-2) receptor antagonist use and gastric cancer. We identified 113 cases and 452 controls and estimated a relative risk (RR) of 2.0 [95% confidence interval (CI) = 1.0-3.9]. When we evaluated the effect of time-since-first-use, the RR estimates were 6.5, 1.2, and 1.0 for 2-4 years of use, 5-9 years, and greater than or equal to 10 years, respectively. The data provide substantial evidence that long-term H-2 antagonist use is not associated with gastric cancer.

引用

页码：434 / 436

页数：3